Efficacy and safety of budesonide/formoterol via a dry powder inhaler in Chinese patients with chronic obstructive pulmonary disease

Current Medical Research and Opinion

Volumn 28, Issue 2, 2012, Pages 257-265

  Zhong, Nanshan ^a   Zheng, Jinping ^a   Wen, Fuqiang ^b   Yang, Lan ^c   Chen, Ping ^d   Xiu, Qingyu ^e   Yao, Wanzhen ^f   Sun, Tieying ^g   Zhao, Ziwen ^h   Shen, Huahao ⁱ   Shi, Yi ^j   Lin, Jiangtao ^k   Li, Qiang ^l  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c XI'AN JIAOTONG UNIVERSITY   (China)

^d GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^e SECOND MILITARY MEDICAL UNIVERSITY   (China)

^f PEKING UNIVERSITY THIRD HOSPITAL   (China)

^g BEIJING HOSPITAL   (China)

^h GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

ⁱ ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^j NANJING GENERAL HOSPITAL OF NANJING MILITARY COMMAND   (China)

^k CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

^l SECOND MILITARY MEDICAL UNIVERSITY   (China)

more..

Author keywords

Budesonide formoterol; Chronic obstructive pulmonary disease; Dry powder inhaler; Lung function

Indexed keywords

BRICASOL; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; PREDNISOLONE ACETATE; TERBUTALINE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHINESE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; POWDER INHALER; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SYMPTOMATOLOGY; THROAT IRRITATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADULT; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; BUDESONIDE; CHINA; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; DRY POWDER INHALERS; ETHANOLAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY FUNCTION TESTS; TREATMENT OUTCOME;

EID: 84863033828     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2011.636420     Document Type: Article

References (15)

1. Pulmonary Disease Group in Respiratory Disease Branch of China Medical Association. Guideline for Chronic Obstructive Pulmonary Disease diagnosis and treatment (Chinese, revised 2007). Chin J Tuberc Respir Dis 2007;30:8-17
2. Zhong N, Wang C, Yao W, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med 2007;176:753-60 (Pubitemid 47598476)
3. National Institutes of Health. Global Initiative for Chronic Obstructive Lung Disease guidelines (GOLD) updated 2008. Available at: http://www. goldcopd.com
4. Barnes PJ. Scientific rationale for inhaled combination therapy with longacting-2-agonists and corticosteroids. Eur Respir J 2002;19:182-91 (Pubitemid 34105586)
5. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81 (Pubitemid 36150304)
6. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-19 (Pubitemid 37540641)
7. Zheng JP, Yang L, Wu YM, et al. The efficacy and safety of combination salmeterol (50 mg)/fluticasone propionate (500 mg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest 2007;132:1756-63
8. Calverley P, Pauwels R, Vestbo J. for the TRISTAN study group. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomized controlled trial. Lancet 2003;361:449-56 (Pubitemid 36173708)
9. Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests. European Community for Steel and Coal. Official statement of the European Respiratory Society. Eur Resp J 1993;6(Suppl 16):5-40
10. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991;85(Suppl B):25-31
11. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992;145:1321-7
12. Jones, PW. St George's Respiratory Questionnaire: development, interpretation and use. Eur Respir Rev 2002;12:63-4 (Pubitemid 36637304)
13. Balanag VM, Yunus F, Yang PC, et al. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 2006;19:139-47 (Pubitemid 43053002)
14. Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomized placebo controlled study. Lancet 2008;371:2013-18 (Pubitemid 351799858)
15. Partridge MR, Schuermann W, Beckman O, et al. Effect on lung function and morning activities of budesonide/formoterol versus salmeterol/fluticasone in patients with COPD. Ther Adv Respir Dis 2009;3:147-57 Current Medical Research & Opinion Volume 28, Number 2 February 2012